23 results on '"Alping, Peter"'
Search Results
2. Validation of the Swedish Multiple Sclerosis registry for pediatric-onset multiple sclerosis.
Catalog
Books, media, physical & digital resources
3. COMBAT‐MS: A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab.
4. Hospital‐Treated Infections and Risk of Disability Worsening in Multiple Sclerosis.
5. Real‐World Healthcare Cost Savings and Reduced Relapse Rate with Off‐Label Rituximab versus Disease‐Modifying Treatments Approved for Relapsing–Remitting Multiple Sclerosis: A Nationwide Cost‐Effectiveness Study
6. Validation of the Swedish Multiple Sclerosis Register : Further Improving a Resource for Pharmacoepidemiologic Evaluations
7. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Non-induction Therapies for Multiple Sclerosis
8. Disease‐modifying therapies in multiple sclerosis: A focused review of rituximab
9. Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations
10. Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
11. sj-docx-1-msj-10.1177_13524585231161492 – Supplemental material for Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
12. Pharmacoepidemiological studies of rituximab and other recent therapies in multiple sclerosis
13. Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
14. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
15. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
16. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
17. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
18. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
19. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
20. Baseline characteristics from the COMBAT-MS study: Initial analyses suggest main driver for therapy choice is geographic location
21. Rituximab in multiple sclerosis : a retrospective observational study on safety and efficacy
22. Rituximab in multiple sclerosis
23. Reply
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.